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Experiments have been performed to enhance the Jurkat cell-killing effects of the cancer
chemotherapy agent bleomycin using electric field pulses of 50–200 kV/cm peak electric field
strength, 150 ns duration, and nanosecond rise time. Dramatic increases in cell killing factors of
1000 were observed with a low dose of bleomycin after treatment with trains of ten or more
pulses at all electric field strengths tested, compared to pulse-only or drug-only treatments. Cell
death occurred within 24 h for treated cells, with some evidence of membrane phosphatidylserine
externalization at 6 h postexposure but no significant increase in caspase activity, indicating that the
primary mode of cell death was not caspase-mediated apoptosis. © 2006 American Institute of
Physics. DOI: 10.1063/1.2194115I. INTRODUCTION
An important goal of cancer chemotherapy is to increase
the effectiveness of drugs with reduced doses to minimize
adverse side effects to the patient. Recent experiments have
demonstrated that a variety of membrane-impermeant anti-
neoplastic drugs, chiefly the antitumor antibiotic bleomycin,
can be loaded into cells using electroporation.1 This type of
treatment has utilized pulses with durations of order 1 ms
and peak electric field strengths in the range of 1–2 kV/cm.
Animal trials2 and ongoing clinical trials have tested such
methods for use with tumors of the skin, as well as tumors
near the skin surface in the head and neck. The electric field
is applied to the tumor using needle or paddle electrodes in
such treatments.3
Bleomycin is a powerful antibiotic agent that reacts in
the presence of metallic ions and oxygen to catalyze double-
strand breaks DSBs in the DNA of living cells.4 Some
single-strand breaks SSBs are also created. This is the same
function performed by ionizing photons in x-ray and gamma
exposures. If the DNA that controls mitosis is damaged, the
cell’s next attempt to divide fails, the cell cycle arrests, and
the cell dies. When sufficient DNA damage occurs to inter-
rupt ordinary cellular functions, cell death rapidly ensues.
Under ordinary conditions, the DNA of cells is protected
from the effects of bleomycin as its motion is blocked by the
intact cell membrane. At equilibrium, a cell’s interior con-
centration of bleomycin is expected to be about 0.05%–0.1%
of any introduced extracellular concentration. Even at these
low rates of uptake, bleomycin has been shown to be reason-
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metabolism, compared to healthy tissue. Electroporation5
has yielded dramatic improvement in this killing effective-
ness.6–9
Agee proposed that cancer chemotherapy could be en-
hanced using ultrawideband UWB electric field pulses,10,11
enabling other methods of electric field coupling to be used
for emerging therapies. In the experiments presented here,
the electroporation of mammalian cells by UWB pulses was
tested to determine the effectiveness of such treatment. These
pulses were of interest because, unlike conventional elec-
troporation wave forms, they contained a large high-
frequency energy content that could be coupled to tissue by
methods not involving direct contact electrodes.
II. EXPERIMENTAL CONFIGURATION
AND PROCEDURES
In the present experiments, ultrawideband electric field
pulses were produced by a high-voltage peaking circuit gen-
erator L-3-Titan Pulse Sciences, San Leandro, CA coupled
to a broadband tapered transmission line. The tapered line
provided uniform 50  impedance along its length, while the
spacing of the electrodes increased from input to termination.
The line was terminated by an array of four 200- low-
inductance Carborundum resistors to provide a 50- resis-
tive termination. The transmission line was enclosed in a
copper-shielded box lined with microwave absorber material
to trap and absorb radiated emissions. The final configuration
was roughly equivalent to a gigahertz TEM GTEM cell.12
For biological cell exposures, a BTX electroporation cu-
vette BTX-Genetronix, Holliston, MA was connected
across the broadband load and filled with cell suspension.
This introduced an impedance mismatch between the genera-
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considerably lower than charging voltages. Cultured Jurkat
cells ATCC, Manassas, VA were suspended in Hanks’ bal-
anced salt solution HBSS at a density of 106 /ml and placed
in cuvettes in the GTEM cell. Cell samples were subjected to
trains of 10–100 UWB pulses at 1 Hz pulse repetition rate.
The charging voltage was −40 kV and the output voltage
was measured with a Northstar PVM-5 high-voltage probe
connected to a Tektronix TDS7404 digital oscilloscope with
data stored in a personal computer PC using LABVIEW. The
peak electric field across each sample was selected by the use
of a cuvette with a 1-, 2-, or 4-mm electrode gap.
The high-voltage output of the UWB generator, mea-
sured across a 4-mm electroporation cuvette loaded with
HBSS, is depicted in Fig. 1. The generator charge voltage
was −40 kV for this test, so some voltage reduction due to
the impedance mismatch was evident. This pulse produced a
60 kV/cm peak electric field across the sample for this
4-mm electrode spacing.
Cells exposed to UWB pulses, both with and without
extracellular bleomycin, were assayed for survival in 24 h
postexposure by trypan blue staining and clonogenic assay.
Clonogenic assay was prepared by serial dilution at 24 h and
incubated for ten days to determine the population of cells
capable of normal replication after treatment.
III. EXPERIMENTAL RESULTS
Data in Fig. 2 compare the survival of cells exposed to
UWB pulse trains to those exposed to both UWB pulses and
bleomycin at a 5 M extracellular concentration, based on
the trypan blue assay. Significant enhancement 90% killed
versus 20% was observed by the application of pulses to
cells together with a low dose of chemotherapy drug. This
bleomycin concentration is 10% of the concentration typi-
cally used for significant cell killing in tissue culture
50 M and is roughly equivalent to the minimum doses
typically used in human cancer chemotherapy. The
95 kV/cm pulsed fields were generated by placing cells in
cuvettes with 2-mm electrode gap spacing.
Clonogenic assay results, showing the level of dilution
FIG. 1. UWB output voltage pulse measured across 4-mm electroporation
cuvette and HBSS solution.required to exclude viable cells from a sample, and thus thenumber density of clonogenically viable cells are depicted in
Fig. 3. These data show that for cells treated with 100 UWB
pulses at 95 kV/cm peak electric field, in the presence of
bleomycin, less than one cell in 10 000 was clonogenically
viable. This represents a 1000-fold enhancement of electro-
chemotherapy over bleomycin alone.
The application of UWB electric field pulses dramati-
cally increased the killing effect of a 5 M bleomycin dose,
resulting in a 1000-fold reduction in the number of viable
cells capable of reproduction. Although much longer pulse
trains were required to achieve this effect for UWB pulses
compared to 100 s pulses,1 it was clear that for a pulse train
resulting in slightly more than 50% killing, a very high de-
gree of killing could be achieved with the addition of a very
low concentration of bleomycin. This result suggested that
the UWB pulses increased the permeability of the cell mem-
branes to allow bleomycin to interact with cellular DNA.
Figure 4 directly compares the killing effects of trains of
ten UWB pulses at varied electric field strengths on
bleomycin-treated Jurkat cells. Viability was assessed by try-
pan blue staining at 24 h. These data indicated that a train of
ten UWB pulses at 50 kV/cm caused sufficient electropora-
tion to deliver a maximum lethal dose of bleomycin to cells
from a 5 M extracellular solution, and higher electric field
strengths and longer pulse trains did not further enhance kill-
FIG. 2. Cytotoxicity of bleomycin and 95 kV/cm UWB pulses.
FIG. 3. Clonogenic viability at 24 h postexposure of Jurkat cells exposed
to 95 kV/cm UWB pulse trains and/or 5 M bleomycin.
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of Jurkat cells by trains of ten UWB pulses without bleo-
mycin was not significantly improved by increasing the av-
erage peak electric field strength from 50 to 195 kV/cm,
even though increasing the number of pulses pulse train
length did markedly increase the cell killing Figs. 2 and 3.
To better understand the biological mechanism by which
cell death occurred in the experiments, exposed cells were
screened for several features of apoptosis. Phosphati-
dylserine inversion on the plasma membrane and activation
of caspases have been observed in mammalian cells exposed
to nanosecond-duration pulses at fields of 50–200
kV/cm.13,14 For the combined UWB/bleomycin treatment
experiments, caspase activity was measured using the
Promega Madison, WI Caspase-Glo 3/7 homogeneous lu-
minescent assay for caspase-3 and caspase-7 activation.
Phosphatidylserine PS inversion to the exterior of the
plasma membrane is a standard cellular assay for apoptosis
and was detected with the PS-binding protein Annexin as the
fluorescent Annexin V-FITC fluoroscein isothiocyanate
conjugate stain from Sigma St. Louis, MO in conjunction
with propidium iodide PI to demonstrate cell viability via
plasma membrane integrity.
The staining of treated Jurkat cells by Annexin V-FITC
and PI is plotted in Fig. 5. At 6 h, none of the treatments
caused a significant number of cells to lose membrane integ-
rity, and the level of PI staining was not significantly differ-
ent for control and treatment samples. However, the com-
bined UWB pulse and bleomycin treatment resulted in a
significant elevation of PS inversion and, consequently, An-
nexin V-FITC staining. As observed by fluorescence micros-
copy, approximately 50% of the cells in the assay sample
expressed inverted PS at 6 h. It was noted that when separate
aliquots from this treatment group were stained and observed
at 24 h, approximately 50% of the cells stained positively for
both PS inversion and loss of membrane integrity, suggesting
that the cells that were killed by the combined treatment
within 24 h were expressing the PS signal at 6 h.
A qualitative observation of the morphology of the cells
was made by light microscopy at 6 h, and the proportion of
FIG. 4. Viability at 24 h postexposure of Jurkat cells exposed to single
trains of ten UWB pulses with and without bleomycin for a range of peak
electric fields 50–195 kV/cm.cells exhibiting unusual morphology swelling, micronucleiformation, shrinkage, and wrinkled appearance agreed very
closely with the Annexin V-FITC staining trend. Apparently,
at 6 h, affected cells expressed both PS inversion on the
membrane and other morphological changes in anticipation
of cell death.
Figure 6 displays the results of the caspase activity as-
say. The assay produced light from a luciferase in the pres-
ence of activated caspase from cell lysate. Caspase activity
was measured at 6 h after exposure of cells to bleomycin and
UWB pulses. While a slight elevation of caspase was evident
for the samples treated with ten UWB pulses, the difference
was less than a two-fold improvement. For an enzyme activ-
ity assay, typically a 10–30-fold increase would be expected
from a significant event or treatment. For the samples treated
with 50 or 100 pulses, there was no significant change in
caspase activity compared to the control samples.
IV. DISCUSSION
It appears that the cells that were killed by the combined
treatment with bleomycin and UWB pulses progressed
through a physiological cell death, rather than undergoing
immediate death due to a direct effect of the UWB pulse
treatment. The cell death featured the physiological PS inver-
sion response and in most cases was likely complete within
FIG. 5. Phosphatidylserine inversion on Jurkat cells 6 h after exposure to
5 M bleomycin and/or a train of ten UWB pulses 50 kV/cm.
FIG. 6. Activation of caspase-3 and caspase-7 in Jurkat cells 6 h after ex-
posure to 5 M bleomycin and/or a train of ten UWB pulses 50 kV/cm.
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some cells retained membrane integrity at 24 h but were not,
in fact, clonogenically viable. This cell death did not exhibit
activation of caspases, which is a prominent feature of apo-
ptotic cell death. However, cells did exhibit morphological
changes which were consistent with apoptosis.
It has been proposed15 that although the duration of an
UWB pulse is several orders of magnitude shorter than the
charging time of a cell membrane, if a pulse of sufficiently
high voltage is applied, a transmembrane voltage of 0.2–1 V
may still be induced, giving rise to pores of 1 nm in diam-
eter. It is estimated that pores of roughly 1.5 nm in diameter
would be required to admit bleomycin molecules, and it is
likely that such a “supraelectroporation” mechanism was re-
sponsible for the increased action of bleomycin in cells sub-
jected to UWB pulses. Furthermore, recent work with
bleomycin electrochemotherapy16 has revealed that there
appear to be multiple regimes for bleomycin effects in cells,
depending on intracellular concentration. In particular,
the results reported by Tounekti et al. suggested that at
low rates of bleomycin uptake, cells were able to repair the
DNA damage caused by the drug, but above a threshold
number of DNA double-strand breaks DSB or in the pres-
ence of a significant number of single-strand breaks SSB,
apoptosis occurred. It was also reported that above a second
threshold, for very high numbers of DSB, cell death termed
“pseudoapoptosis” occurred featuring some, but not all, of
the features of apoptosis. Similar results were observed17 in
experimental tumor model systems. This mechanism is sup-
ported by the data in the experiments reported here.
The majority of work reported to date on UWB and
similar ultrashort electrical pulses has focused on the effects
of coupling the electric field pulses to intracellular
membranes14 and modulating physiological functions in
cells.18 However, the effect of such UWB pulses on the
plasma membrane has been noted but not previously inves-
tigated thoroughly. The present experiments have demon-
strated that ultrashort pulses of 60 ns duration or greater are
useful for modulating cellular uptake of very small molecu-lar species in addition to the intracellular effects reported in
previous studies. It is expected that such transmembrane up-
take would be possible for even shorter pulses approxi-
mately 10 ns in duration, although the electric field
strengths required to achieve membrane permeabilization
might be considerably higher than in the present study.
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